GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong growth prospects with raised revenue guidance, robust exome and genome revenue growth, and increased adjusted gross margin. The company's strategic initiatives in NICU, pediatrics, and international markets, along with AI and automation investments, further enhance the outlook. Despite some uncertainties in the Q&A, the overall sentiment is positive, supported by optimism in new market penetration and operational efficiency improvements. The absence of negative catalysts like margin decline or guidance cuts solidifies the positive sentiment.
Key Financial Performance
Quarterly Revenue $121 million, up 27% year-over-year. Growth driven by foundational markets like geneticists and pediatric specialists.
Full Year Revenue $428 million, supported by 54% exome and genome revenue growth. Growth attributed to increased adoption and market penetration.
Exome and Genome Revenue (Quarterly) $104 million, an increase of 32% year-over-year. Organic growth rate was 42% excluding a $6.8 million one-time payer recovery in Q4 last year.
Exome and Genome Test Volume (Quarterly) 27,761 tests, showing consistent acceleration from 24% growth in Q1 to 34% growth in Q4. Growth driven by increased adoption among geneticists and pediatric specialists.
Average Reimbursement Rate (ARR) for Exome and Genome $3,750 in Q4 2025, up from $3,000 in 2024 and $2,500 in 2023. Increase attributed to mix dynamics and higher adoption of genome testing.
Adjusted Gross Margin 71% for both Q4 and full year 2025, up from 65% in 2024 and 45% in 2023. Improvement driven by scale and cost efficiencies.
Adjusted Net Income $4.4 million for Q4 and $4.8 million for the full year 2025, demonstrating leverage in the business model.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA breakthrough device designation: GeneDx received this designation, positioning it to become the first FDA-authorized comprehensive genomic solution in its category.
Infinity data set: The world's largest and most diverse rare disease data set, composed of over 2.5 million rare genetic tests, 1 million exomes and genomes, and 8 million phenotypic data points.
AI gene ranker, Multiscore: Proprietary AI tool analyzing billions of data points to identify genes causing patient symptoms, improving efficiency and turnaround times.
General pediatrics: Opening new markets to reach patients earlier, with a 1-minute ordering experience launching in summer 2026.
NICU: Dedicated team targeting neonatal intensive care units, with steady growth expected in 2026.
Prenatal diagnostics: Launched exome and genome tests for patients with abnormal ultrasounds, targeting maternal fetal medicine specialists.
International expansion: Building an international strategy centered around software and interpretation as a service, with initial execution in key geographies.
Revenue growth: Quarterly revenues reached $121 million, with full-year revenues at $428 million, driven by 54% growth in exome and genome revenue.
Sales force expansion: Sales team expanded from 50 reps in 2025 to 75 in 2026 to drive adoption in foundational markets.
Adjusted gross margin: Improved to 71% in 2025, up from 65% in 2024 and 45% in 2023.
Market penetration: Achieved 80% clinician penetration among geneticists and 30% among pediatric specialists, with significant room for growth.
Layered growth strategy: Focused on activating new clinicians, increasing utilization, and introducing testing to new markets.
Future markets: Exploring genomic newborn screening, telemedicine channels, and leveraging data for biopharma in precision medicine.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Penetration Challenges: Despite having 80% clinician penetration among geneticists, only 30% of eligible patients are being reached. Pediatric specialists have only reached 15% of eligible patients, and new markets like general pediatricians and NICU have clinician adoption in the single digits.
Supply Chain and Cost Challenges: Genome testing costs more than exome testing due to higher reagent costs, which could impact profitability. While costs are expected to decrease over time, this remains a short-term challenge.
Regulatory and Market Adoption Risks: The adoption of new testing standards, such as exome to genome reflex testing, depends on clinician education, guidelines, and market acceptance, which could delay growth.
Operational Scaling Risks: The company is nearly tripling its sales force and expanding into new markets, which requires significant investment and operational efficiency to ensure productivity and ROI.
Economic and Seasonal Risks: Seasonal dynamics, such as deductible resets, impact Q1 volumes and collection rates. Additionally, weather disruptions like storms have caused delays in testing volumes.
Competitive Pressures: While GeneDx holds a leadership position, maintaining an 80% share in competitive markets requires continuous innovation and investment to fend off competitors.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: GeneDx reaffirmed its full-year 2026 revenue guidance, projecting total revenues in the range of $540 million to $555 million.
Exome and Genome Volume Growth: The company expects exome and genome volume growth of 33% to 35% in 2026, with foundational markets contributing 25% to 27% and expansion markets contributing 7% to 8%.
Adjusted Gross Margin: GeneDx anticipates an adjusted gross margin of approximately 70% for 2026, considering mix shift dynamics.
Adjusted Net Income: The company expects to remain adjusted net income positive for the full year and each individual quarter of 2026, despite a heavy investment cycle.
Market Expansion: GeneDx is expanding into six untapped markets, including general pediatrics, NICU, prenatal diagnostics, adult specialists, and international markets. The company is nearly tripling its sales force to capture growth opportunities.
General Pediatricians Market: The company plans to launch a custom-designed 1-minute ordering workflow for general pediatricians in mid-2026, with volumes expected to pick up in Q4 2026 and accelerate into 2027.
NICU Market: GeneDx expects steady growth in the NICU market in 2026, supported by a dedicated team of 10 representatives.
Prenatal Diagnostics: The company is targeting maternal fetal medicine specialists with a small team of 10 representatives to drive utilization in prenatal diagnostics, with ramp-up expected in Q2 2026.
International Strategy: GeneDx is building an international strategy centered around software and interpretation as a service, with contributions expected in late 2026 and beyond.
Future Markets: The company is laying the groundwork for genomic newborn screening, telemedicine channels, and leveraging its data set for biopharma applications in precision medicine.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the assumption of a recent trend reversal in foundational test volumes, and what gives confidence in this assumption?
A:Kevin Feeley explained that the confidence comes from factors like the large amount of white space available in terms of penetration rates, activating new clinicians, and converting from single-gene and multi-gene tests to exome and genome tests. He also highlighted the strength of their commercial team and the planned tripling of their rare disease sales team.
Q:What are the puts and takes for quarterly cadence this year on volumes, ASPs, and gross margins?
A:Kevin Feeley stated that Q1 is typically the low point in terms of volume and reimbursement rates due to deductible factors and weather, with Q4 being the strongest. He also mentioned variability in operating days and seasonal factors like school and holiday calendars. Gross margins ended the year at 71%, with the exome genome portfolio operating in the 80s. They plan to optimize genome costs and reimbursement, with a conservative view on gross margin in the guide.
Q:Should we expect a more significant sequential decline in test volumes in Q1 compared to last year?
A:Kevin Feeley indicated that a decline of 300 to 400 tests in Q1 off of Q4 sequentially would not be unexpected, with the guide anchored in a 33% to 35% baseline expectation for Q1 due to weather and deductible resets.
Q:What is the base for the nearly tripling of the commercial footprint?
A:Kevin Feeley explained that the base was about 60 sales reps in 2025, with 50 calling on outpatient markets and 10 focused on the NICU. They are adding about 100 more reps, including 50 new sales reps for general pediatricians, 10 new prenatal reps, and 10 more NICU reps.
Q:What are the upside opportunities not baked into the guidance?
A:Kevin Feeley mentioned potential upside in general pediatricians and prenatal markets, with volumes expected to ramp following the launch of a new customer experience in Q2/Q3. He also noted conservative assumptions for reimbursement rates in new outpatient markets and potential growth in the NICU setting.
Q:How does GeneDx's test performance compare to competitors, and how do they plan to maintain or accelerate market share?
A:Katherine Stueland stated that GeneDx delivers 2x the accuracy of other exome or genome tests due to their Infinity reference data. They also have faster turnaround times (2 weeks) and cost-effective operations. They plan to continue investing in R&D and integrating new technologies like long-read sequencing to maintain industry-leading diagnostic yield.
Q:What are the key metrics for tracking success in the general pediatrics market?
A:Katherine Stueland mentioned tracking the number of new clinicians, time to ramp, average reimbursement rates, and the utilization of 1-minute ordering. They anticipate a Q4 inflection with reps becoming productive and the launch of 1-minute ordering.
Q:How does GeneDx plan to grow its penetration rate in the NICU setting?
A:Katherine Stueland highlighted a new strategy focusing on selling directly to neonatologists, peer-to-peer KOL strategies, and simplifying the selling strategy with tools like the SeqFirst protocol. Early signs in Q1 are positive, and they are considering adding more reps.
Q:What is the outlook for pricing and reimbursement in 2026?
A:Kevin Feeley stated that the guide assumes no new Medicaid states or Medi-Cal pricing. They have taken a conservative view on reimbursement rates in new outpatient markets, expecting initial denial rates similar to past experiences but aiming to improve over time.
Q:What is the contribution of new growth drivers like NICU, prenatal, and pediatricians to the 7%-8% growth from expansion markets?
A:Kevin Feeley indicated that the NICU will be the largest contributor, followed by prenatal and pediatricians. The NICU is showing encouraging early signs, while prenatal and pediatricians are expected to ramp later in the year.
Q:What is the strategy for leveraging EMRs like Epic in 2026?
A:Katherine Stueland explained that the focus is on using Epic to unlock new customers, particularly general pediatricians and health systems, rather than current customers. They are also releasing 1-minute ordering to complement Epic.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer or lacked clarity on the following: 1. Specific details on how much of the 300,000 annual patients among geneticists are not suitable for next-gen testing versus single or multi-gene panels. 2. The exact timeline and impact of potential legislation like H.R.7118 and the Florida Sunshine Genetics Act. 3. Detailed breakdown of the contribution from new growth drivers like NICU, prenatal, and pediatricians to the overall growth. 4. Specific financial impact of the Komodo Health partnership on the pharma business.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI enabler
AI gene
AI model
Americans average
Children recommendation
FDA breakthrough
FDA solution
Feeley Chief
GeneDx FDA
GeneDx Infinity
GeneDx need
GeneDx patient
GeneDx revenue
GeneDx specialist
GeneDx test
Infinity compound
Infinity diagnosis
Infinity interpretation
Infinity resource
Infinity surface
Infinity world
Katherine finish
adult
cancer
diagnosis scale
diagnostics
disease patient
element
expansion
leader
mainstream
market geneticist
market sale
moment
patient power
precision
rep
sale force
standard
symptom
utilization clinician
WGS Transcript
GeneDx Holdings Corp. (WGS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
Positive5-4
The financial performance shows strong revenue growth of 25% YoY and improved gross margins, indicating operational efficiency. Despite a net loss, the reduction from the previous year is positive. The reaffirmed revenue guidance for 2026 and market expansion plans into new sectors and geographies suggest optimism. The company's strategic initiatives, such as expanding into new markets and increasing sales force, indicate growth potential. However, the lack of discussion on operational updates and strategic initiatives during the call slightly tempers the positivity, leading to a 'Positive' sentiment.
GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call summary and Q&A indicate strong growth prospects with raised revenue guidance, robust exome and genome revenue growth, and increased adjusted gross margin. The company's strategic initiatives in NICU, pediatrics, and international markets, along with AI and automation investments, further enhance the outlook. Despite some uncertainties in the Q&A, the overall sentiment is positive, supported by optimism in new market penetration and operational efficiency improvements. The absence of negative catalysts like margin decline or guidance cuts solidifies the positive sentiment.
WGS Slides
WGS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
